FDA Approved: NEXLIZET — Supplemental Application (Esperion Therapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Nexlizet (bempedoic acid and ezetimibe) by Esperion Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Mixed Dyslipidemia

Drugs mentioned

• NEXLIZET (bempedoic acid and ezetimibe)

Snippet

SUPPL AP for NEXLIZET (BEMPEDOIC ACID AND EZETIMIBE)